SYDNEY Australia 8 August 2019: Recce Pharmaceuticals Limited (ASX: RCE), the Company developing a new class of broad-spectrum synthetic antibiotics, today announced the European Patent Office has granted its patent applications for wholly owned RECCE® antibiotics, including lead compound RECCE® 327 furthering marketing/manufacturing monopolies and expanding clinical indications.
The patent family titled ‘Copolymer for use in a method of treatment of a parenteral infection’, is a second family of 15 claims, all of which were granted by the European Patent Office.
The patent relates to methods of manufacture, administration and application to treat a broad range of common human infections, providing Recce intellectual property protection until November 2035.
Over the last 12 years, anti-microbial resistance has increased by 32% in Europe1. The grant of this patent reaffirms RECCE® antibiotics capability against Gram-positive and Gram-negative bacteria including their superbug forms, with particular claim to efficacy against: Proteus spp, Serratia spp, Pseudomonas aeruginosa, Neisseria meningitidis, Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, coagulase-negative Staphylococcus spp, Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus spp. The listed bacteria are of serious consequences if contracted.
Recce Pharmaceuticals Chairman Dr John Prendergast stated: “The granting of this important patent family in Europe, together with the existing US patent portfolio is an important commercial and technical milestone as we continue to execute our intellectual property strategy and grow our worldwide patent protection for our unique synthetic antibiotic.”
1 European Biotechnology, Life Science and Industry Magazine – Antibiotic resistance spreading across Europe.
About Recce Pharmaceuticals
Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development of a New Class of Synthetic Antibiotics with Broad Spectrum activity, addressing the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate RECCE® 327 has been designed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. The FDA awarded RECCE® 327 Qualified Infectious Disease Product (QIDP) designation under the Generating Antibiotic Initiatives Now (GAIN) Act - labelling RECCE® 327 for Fast Track designation, plus 10 years of market exclusivity post approval. Recce’s expanding anti-infective pipeline seeks to exploit the unique capabilities of RECCE® technologies targeting synergistic, unmet medical needs.
Issued for and on behalf of Recce Pharmaceuticals by Instinctif Partners.
For more information please visit recce.com.au or contact firstname.lastname@example.org.
Sue CharlesManaging Partner